Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Indivior

The transatlantic opioid crisis

The transatlantic opioid crisis

These worrying trends, official investigations in the UK, like The Gosport Inquiry in 2018, and allegations made against British pharma business, Indivior, create fertile ground for potential litigation on these shores.

As the opioid crisis grabs the headlines, the search for safe treatments continues

As the opioid crisis grabs the headlines, the search for safe treatments continues Indivior’s Gilles Picard charts a path to greater patient access and new therapies. ... It is hardly the easiest climate in which to market an opioid-based drug to treat addiction, while at the same time developing new treatments, but Indivior, the

Reckitt hammered by $1.4bn opioid settlement bill

Reckitt hammered by $1.4bn opioid settlement bill The federal investigation centred on a former Reckitt pharmaceutical subsidiary – spun off in 2014 and renamed Indivior – and marketing practices it deployed for Suboxone between 2006 and 2015. ... Indivior is also in the firing line, and in April

Drug launches to watch in 2019

Drug launches to watch in 2019 Compared with a similar treatment marketed by Indivior, the drug has advantages in flexibility.

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

Horizon Discovery and C4X to harness CRISPR for new cancer drugs C4XD has already had success in this strategy, having signed an outlicensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m.

1 2 3 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Founded in 201, Market Access Transformation (MAT) specializes in developing agile technology platforms that enable the healthcare community to exchange...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...